2.
Clinical and pathological characteristics of cases
| Case No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; PST, primary systemic therapy; MRM, modified radical mastectomy; ALND, axillary lymph node dissection; TCH, docetaxel 75 mg/m2, carboplatin AUC=5-6, trastuzumab 8 mg/kg in the first week followed by 6 mg/kg every 3 weeks; TA, docetaxel 75 mg/m2 or paclitaxel 175 mg/m2, combined with epirubicin 75 mg/m2 every 3 weeks; AC-T, doxorubicin and cyclophosphamide followed by paclitaxel; H, trastuzumab; AI, aromatase inhibitors; TAM, tamoxifen; Neg., negative; Pos., positive; Y, yes; N, no. | |||||||||||
| Age (year) | 56 | 54 | 59 | 59 | 29 | 57 | 67 | 56 | 75 | 44 | 34 |
| MRI finding | Neg. | Neg. | 1.5 cm × 1.7 cm ×1.7 cm mass in the lateral lower quadrant of the right breast (false positive) | Neg. | 1.4 cm × 2.0 cm ×2.4 cm mass in lateral upper quadrants of the right breast | Refused | Refused | 0.7 cm × 0.8 cm × 0.7 cm mass in the upper quadrant of the right breast | Neg. | 0.5 cm × 0.4 cm × 0.4 cm mass in the inner quadrant of the left breast (false positive) | Neg. |
| Grade | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 |
| N stage | N1 | N2 | N3 | N2 | N2 | N2 | N1 | N2 | N1 | N1 | N2M1 |
| ER | Neg. | 2% weak Pos. | 90% strong Pos. | 85% middle Pos. | Neg. | Neg. | Neg. | Neg. | 50% middle Pos. | 40% middle Pos. | Neg. |
| PR | Neg. | 2% middle Pos. | Neg. | Neg. | Neg. | Neg. | Neg. | Neg. | Neg. | 85% strong Pos. | <1% weak Pos. |
| HER2 | Neg. | Neg. | Neg. | Pos. | Neg. | Pos. | Neg. | Pos. | Pos. | Pos. | Pos. |
| Ki67 | 80% | 90% | 10% | 70% | 80% | 40% | 70% | 80% | 90% | 25% | 70% |
| PST | TA×4 | TA×6 | TA×6 | TCH×6 | TAC×6 | N | N | N | N | N | TCH-H |
| Surgery | MRM | MRM | MRM | MRM | MRM | ALND | MRM | MRM | ALND | MRM | N |
| Post-surgery breast pathology | Sclerosing adenosis | Adenosis | Slight proliferation | Slight proliferation | G5, 2 cm fibrosis, no residual invasive ductal cancer and DCIS | A little diffuse invasive ductal cancer cells, difficult to measure T | 0.4 cm invasive ductal cancer | Adenosis | |||
| Post-surgery LN pathology | 1/19, with fibrosis | 6/28, all of 6 LNs with fibrosis | 13/29, with a little fibrosis | 1/19, two with fibrosis | 5/13, all the 5 LNs with fibrosis | 7/15 | 1/10 | 4/18 | 1/15 | 3/20 | |
| LN pathological evaluation | N-C | N-C | N-C | N-C | N-C | ||||||
| Adjuvant chemotherapy | TA×2 | N | N | N | N | Refused | Refused | AC-T | AC-T | ||
| Adjuvant anti-HER2 | N | N | N | H to 1 year | N | Refused | N | Refused | Refused | Refused | |
| Radiotherapy | Y | Y | Y | Refused | Y | Refused | Refused | Y | Refused | Refused | Refused |
| Endocrine therapy | N | AI | AI | AI | N | N | N | AI | TAM | ||
| Follow-up (month) | 15 | 21 | 26 | 6 | 23 | 53 | 96 | 43 | 67 | 8 | 33 |
| Events | 11 months after ALND, ipsilateral breast cancer | ||||||||||